|Mr. Andrew J. Rae BSc, MBA||Co-Founder, CEO, Pres & Director||309.5k||N/A||50|
|Mr. Michael Liggett CPA, CA, Bsc. Pharm.||CFO, Corp. Sec. & Director||19.72k||N/A||57|
|Dr. Peter Hnik M.D., MHSc||Chief Medical Officer||196.64k||N/A||61|
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense C-Raf kinase inhibitor program; iCo-008 (Bertilimumab), a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic indications; and Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
iCo Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.